drugset
drugset / Trial / NCT06589726

A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants

NCT06589726 ↗

Phase 1 Completed 40 enrolled Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to assess potential effects of enpatoran on cardiac repolarization (i.e. prolongation of QT interval).

Timeline

Start
2024-09-10
Primary completion
2024-12-02
Completion
2024-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Enpatoran Small molecule — Oral
Subject Moxifloxacin Small molecule — Oral

Indications

No indication recorded.